Literature DB >> 15001976

Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.

Kwadwo Amankwa1, Subramaniam C Krishnan, James E Tisdale.   

Abstract

The fluoroquinolone antibiotics sparfloxacin, grepafloxacin, gatifloxacin, and levofloxacin have been reported to cause torsades de pointes. Pre-existing risk factors increase vulnerability to this life-threatening arrhythmia. In a 65-year-old woman with a history of hypertension, coronary artery disease, systemic lupus erythematosus, and osteomyelitis, QTc interval prolongation (605 ms) and torsades de pointes developed after the initiation of levofloxacin, 250 mg intravenously once daily. The patient was hypokalemic and mildly hypomagnesemic before the initiation of levofloxacin and at the time of occurrence of torsades de pointes. The QTc interval decreased to 399 ms within hours of discontinuation of the levofloxacin, after which she had no further arrhythmias. In this and the majority of other published cases of fluoroquinolone-associated torsades de pointes, patients had at least 1 risk factor for the arrhythmia, and most had multiple risk factors. Fluoroquinolone antibiotics should be avoided whenever possible in patients with pre-existing risk factors for torsades de pointes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15001976     DOI: 10.1016/j.clpt.2003.11.376

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

Review 1.  Safety considerations of fluoroquinolones in the elderly: an update.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2010-03-01       Impact factor: 3.923

Review 2.  Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation.

Authors:  Marek Malik
Journal:  Drug Saf       Date:  2016-07       Impact factor: 5.606

Review 3.  Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms.

Authors:  Gerrit Frommeyer; Lars Eckardt
Journal:  Nat Rev Cardiol       Date:  2015-07-21       Impact factor: 32.419

Review 4.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 5.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.

Authors:  Ari J Alexandrou; Rona S Duncan; Anneli Sullivan; Jules C Hancox; Derek J Leishman; Harry J Witchel; Joanne L Leaney
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

7.  Skin and skin structure infections: treatment with newer generation fluoroquinolones.

Authors:  Philip Giordano; Kurt Weber; Gail Gesin; Jason Kubert
Journal:  Ther Clin Risk Manag       Date:  2007-06       Impact factor: 2.423

Review 8.  Long QT Syndrome: An Emerging Role for Inflammation and Immunity.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Franco Laghi-Pasini
Journal:  Front Cardiovasc Med       Date:  2015-05-27

Review 9.  Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.

Authors:  Francesco Pecora; Giulia Dal Canto; Piero Veronese; Susanna Esposito
Journal:  Microorganisms       Date:  2021-05-17

10.  Dynamics of the QTc interval over a 24-h dose interval after start of intravenous ciprofloxacin or low-dose erythromycin administration in ICU patients.

Authors:  Florine A Berger; Willem van Weteringen; Heleen van der Sijs; Nicole G M Hunfeld; Jeroen J H Bunge; Natasja M S de Groot; Patricia M L A van den Bemt; Teun van Gelder
Journal:  Pharmacol Res Perspect       Date:  2021-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.